Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Application of ihMT MRI in Multiple Sclerosis

NCT: NCT03600779 · RECRUITING

NCT IDNCT03600779
StatusRECRUITING
Start Date2018-06-14
Completion2028-08-14
SponsorAssistance Publique Hopitaux De Marseille (OTHER)
First posted
Last updated

Brief Summary

The development of in vivo biomarkers sensitive to myelin disruption represents a major clinical need to be able to monitor the demyelination processes as well as the effect of remyelinating therapies in multiple sclerosis. The investigators recently proposed a technique, derived from the conventional magnetisation transfer (MT): inhomogeneous Magnetisation Transfer (ihMT). In preliminary studies, this simple-to-implement and robust technique has shown great sensitivity for evaluating the demyelination processes. The goal of the project is to evaluate the ability of ihMT to measure and describe the spontaneous demyelination and remyelination processes involved in active lesions in a population of patients with MS at the the disease onset.

Frequently Asked Questions

What is Application of ihMT MRI in Multiple Sclerosis?

Application of ihMT MRI in Multiple Sclerosis is a clinical trial registered under NCT03600779. Current status: RECRUITING.

What is the status of NCT03600779?

The current status of NCT03600779 (Application of ihMT MRI in Multiple Sclerosis) is: RECRUITING.

When did Application of ihMT MRI in Multiple Sclerosis start?

Application of ihMT MRI in Multiple Sclerosis started on 2018-06-14.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.